Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efocipegtrutide in Obese Subjects With NAFLD
NCT03744182Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in non-alcoholic fatty liver disease (NAFLD) and obesity comparing HM15211 with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events at 12 weeks, Incidence of Clinical Renal Function Lab Abnormalities at 12 weeks and 2 more. Started Nov 2018; status: completed.
02
Drugs
efocipegtrutide
03
Conditions
non-alcoholic fatty liver disease (NAFLD)obesity
Beyond the preview
Go deeper on NCT03744182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744182.